TP53 and cancer: In contrast to wild-type (wt) p53, cancer-associated point mutations occur predominantly in its DNA-binding domain and the derived p53 mutant(s) (mt(s)) suppress wt p53 functions(s) and enhance tumor progression by promoting genome instability, drug and immune system resistance, and even metastatic phenotype (Figure 1).